ArticleActa ophthalmologica2026
Blindness and prognostic factors after trabeculectomy with mitomycin C in patients with open-angle glaucoma with long-term follow-up.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo determine the long-term blindness rate and related prognostic factors in eyes with open-angle glaucoma after trabeculectomy using adjunctive mitomycin C (MMC).
methodsThe retrospective cohort study included 714 eyes from 714 patients with open angle glaucoma who underwent trabeculectomy using MMC. We defined blindness based on the World Health Organization (WHO) criteria as best-corrected visual acuity (BCVA) <20/400 and/or central visual field <10°. We used Kaplan-Meier analysis to estimate the nonblindness rate postsurgery.
resultsPreoperatively, the mean (standard deviation) BCVA, intraocular pressure (IOP) and mean deviation (MD) using the central 30-2 program of Humphrey Field Analyser were 0.11 ± 0.31, 20.5 ± 7.1 mmHg, and -16.93 ± 7.16 dB. The follow-up period was 11.7 ± 7.3 years, and the mean postoperative IOP reduction rate was 41.4% ± 20.2%. The 10- and 20-year cumulative survival rates were 87.8% and 82.6%. The survival rates were significantly higher in the groups with better preoperative BCVA, preserved preoperative MD, and higher mean postoperative IOP reduction rate (all p < 0.001). Moreover, the analysis of prognostic factors for blindness showed that the multivariate hazard ratios for preoperative BCVA, preoperative MD and mean postoperative IOP reduction rate were 4.74, 0.92 and 0.97, respectively (all p < 0.001).
conclusionsOne-eighth and one-sixth of the eyes became blind at 10 and 20 years post-trabeculectomy using MMC. Preoperative severe visual impairment and visual field loss and postoperative nonsustained IOP reduction were identified as independent prognostic factors leading to blindness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.